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Predictive or treatment selection biomarkers are usually evalu-
ated in a subgroup or regression analysis with focus on the treatment-
by-marker interaction. Under a potential outcome framework (Huang,
Gilbert and Janes [Biometrics 68 (2012) 687–696]), a predictive
biomarker is considered a predictor for a desirable treatment benefit
(defined by comparing potential outcomes for different treatments)
and evaluated using familiar concepts in prediction and classifica-
tion. However, the desired treatment benefit is unobservable because
each patient can receive only one treatment in a typical study. Huang
et al. overcome this problem by assuming monotonicity of potential
outcomes, with one treatment dominating the other in all patients.
Motivated by an HIV example that appears to violate the monotonic-
ity assumption, we propose a different approach based on covariates
and random effects for evaluating predictive biomarkers under the
potential outcome framework. Under the proposed approach, the pa-
rameters of interest can be identified by assuming conditional in-
dependence of potential outcomes given observed covariates, and a
sensitivity analysis can be performed by incorporating an unobserved
random effect that accounts for any residual dependence. Application
of this approach to the motivating example shows that baseline viral
load and CD4 cell count are both useful as predictive biomarkers for
choosing antiretroviral drugs for treatment-naive patients.
1. Introduction. Much of contemporary medical research is focused on
treatment effect heterogeneity, that is, the fact that the same treatment
can have different effects on different patients. The increasing awareness of
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Fig. 1. Nonparametric regression analysis of the THRIVE data: smoothed estimates
(thicker lines) and pointwise 95% confidence intervals (thinner lines) for treatment-specific
response rates as functions of baseline viral load (left) and CD4 cell count (right).
treatment effect heterogeneity has motivated the development of predictive
biomarkers for identifying the subpopulation of patients who would actually
benefit from a new treatment [e.g., Simon (2008, 2010)]. Classical examples
of predictive biomarkers include genetic markers for cancer treatment, such
as the OncoType Dx multi-gene score for breast cancer [Paik et al. (2004)]
and the K-RAS gene expression level for colorectal cancer [Karapetis et al.
(2008)]. This article is motivated by a new and growing interest in the possi-
bility of using baseline viral load or CD4 cell count as a predictive biomarker
for treating human immunodeficiency virus type 1 (HIV-1).
Evaluation of a predictive biomarker is usually based on a subgroup or
regression analysis comparing treatment effects on different subpopulations
defined by the biomarker [e.g., Gail and Simon (1985), Russek-Cohen and
Simon (1998), Pocock et al. (2002)]. Under this approach, the performance
of a predictive biomarker is measured by the interaction between marker
value and treatment assignment in a regression model for the clinical out-
come of interest, which will be referred to as an outcome model. For exam-
ple, consider the THRIVE study, a phase 3, randomized, noninferiority trial
comparing rilpivirine, a newly developed nonnucleoside reverse transcriptase
inhibitor, with efavirenz in treatment-naive adults infected with HIV-1 [Co-
hen et al. (2011)]. The outcome of primary interest is a binary indicator of
virologic response at week 48 of treatment (see Section 4 for details). Our
consideration of baseline viral load and CD4 cell count as predictive biomark-
ers (for choosing between efavirenz and rilpivirine) is motivated by Fig-
ure 1, which shows nonparametric estimates of treatment-specific response
rates as functions of marker value, separately for each biomarker. Figure 1
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suggests a qualitative interaction between treatment and each biomarker,
with rilpivirine favored over efavirenz for higher values of baseline CD4 cell
count and lower values of baseline viral load. Because the statistical signifi-
cance in Figure 1 is not straightforward to assess, a simple logistic regression
analysis that includes treatment, marker and their interaction is performed
(separately for each marker), and the resulting p-value for the treatment-
by-marker interaction is 0.059 for viral load and 0.031 for CD4 cell count.
While informative about possible interactions, Figure 1 is less transparent
about the predictive performance of these biomarkers and their comparison.
Huang, Gilbert and Janes (2012) point out that a strong interaction is not
sufficient for adequate performance of a predictive biomarker, that the scale
of the interaction coefficient depends on the functional form of the outcome
model, and that the interaction-based approach is ill-suited for develop-
ing combination markers. These authors also propose a potential outcome
framework where a predictive biomarker is—as the term suggests—treated
as a predictor for a desirable treatment benefit. Note that a treatment ben-
efit is necessarily the result of comparing potential outcomes for different
treatments applied to the same patient. Under this perspective, predictive
biomarkers should be evaluated using familiar measures in prediction and
classification [e.g., Zhou, Obuchowski and McClish (2002), Pepe (2003), Zou
et al. (2011)]. Specifically, one should consider the true and false positive
rates of a binary marker and the receiver operating characteristic (ROC)
curve for a continuous marker. This approach allows different markers to be
compared on the same scale and facilitates the development of combination
markers.
The objective of this article is to evaluate and compare baseline viral load
and CD4 cell count as predictive biomarkers under the potential outcome
framework. It is important to distinguish this objective from the related
problems of identifying potential markers, combining several markers into
a hybrid marker, choosing the cutoff point for a given marker and, more
generally, developing an individualized treatment strategy. Variable selec-
tion techniques such as lasso-based methods have been used to select and
combine genetic markers [e.g., Tian et al. (2012)]. Nonparametric multivari-
ate methods [e.g., Su et al. (2008), Foster, Taylor and Ruberg (2011), Qian
and Murphy (2011)] and semiparametric methods [e.g., Zhang et al. (2012)]
have been used to develop a treatment rule (i.e., a set of criteria for selecting
patients), which can be considered a binary hybrid marker obtained by com-
bining multiple markers. A natural question that arises from the THRIVE
study is whether or how to combine baseline viral load and CD4 cell count
into a hybrid marker with improved predictive accuracy. While that ques-
tion is beyond the scope of this article, we note that the potential outcome
framework and the proposed methods are applicable to any given marker.
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Once a hybrid marker is developed, it can be evaluated and compared to
the individual markers in the same framework using the same methods.
An analytical challenge for the potential outcome framework is that the
desired treatment benefit, which involves potential outcomes under different
treatments, is usually unobservable because each patient can receive only
one treatment in a typical study. A possible exception to this limitation is
a cross-over study, which has its own issues [e.g., Poulson, Gadbury and
Allison (2012)] and will not be discussed in this article. In a typical clinical
study such as the THRIVE study, the standard methodology in prediction
and classification is not directly applicable to a predictive biomarker. To
address this issue and the resulting identification problem, Huang, Gilbert
and Janes (2012) make a monotonicity assumption, namely, that one treat-
ment dominates the other in all individual patients, and suggest a sensitivity
analysis for possible departures from the monotonicity assumption. While
the monotonicity assumption may be plausible in some situations such as
vaccine trials, it may be less appealing as a starting point in other situations.
In the THRIVE study, for example, the presence of a qualitative interaction
(in the sense that neither treatment has a higher response rate for all realis-
tic marker values) implies that neither treatment is dominant in all patients.
Additionally, the approach of Huang, Gilbert and Janes (2012) is developed
for a binary outcome and not readily extensible to other types of outcomes.
In this article, we propose alternative methods that do not require mono-
tonicity or assume a binary outcome. Our first step is to account for the
dependence between potential outcomes (for different treatments applied to
the same patient) by adjusting for relevant covariates, such as demographic
variables and baseline characteristics. If the set of measured covariates is
sufficient for explaining the dependence between potential outcomes, the
aforementioned performance measures can then be identified by assuming
conditional independence of potential outcomes given covariates. Possible
violations of this assumption can be addressed by introducing a random ef-
fect to account for residual dependence. In the next section we formulate
the problem in terms of potential outcomes and provide a general ratio-
nale for the proposed approach. The proposed methods are then described
in Section 3 and applied to the THRIVE study in Section 4. The article
ends with a discussion in Section 5. Some technical details are provided in
a supplemental article [Zhang et al. (2014)].
2. Notation and rationale. Suppose a randomized clinical trial is con-
ducted to compare an experimental treatment with a control treatment,
which may be a placebo or a standard treatment, with respect to a clinical
outcome of interest, which may be discrete or continuous. Because there is
only one outcome of primary interest in the THRIVE study, we will work
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with a scalar outcome unless otherwise noted. However, most of our method-
ology is readily applicable to a vector-valued outcome, with the exception
of the sensitivity analysis in Section 3.2 (described fully in Web Appendix
B). For a generic patient in the target population, let Y (t) denote the po-
tential outcome that will result if the patient receives treatment t (0 for
control; 1 for experimental). Note that the Y (t), t = 0,1, cannot both be
observed at a given time. Let T denote the treatment assigned randomly
to a study subject, thus T is a Bernoulli variable independent of all base-
line variables. Without considering noncompliance, which is negligible in
the THRIVE study, we assume that T is also the actual treatment given to
the subject, and write Y = Y (T ) for the actual outcome. Should noncom-
pliance become a major issue, we could take an intent-to-treat perspective
and compare treatment assignments or use analytical techniques to recover
the actual treatment effect [e.g., van der Laan and Robins (2003)]. We as-
sume that large values of Y are desirable. Where necessary, the subscript
i = 1, . . . , n will be attached to random variables to denote individual pa-
tients in the trial.
Our interest is in evaluating a predictive biomarker Z, a baseline variable
which may be binary or continuous, with higher marker values support-
ing the use of the new treatment. The biomarker Z is intended to identify
the subpopulation of patients who would benefit from the new treatment
relative to the control. It can be a continuous variable as in our moti-
vating example or a binary one such as a treatment rule developed us-
ing nonparametric multivariate methods. Let the desired treatment bene-
fit be indicated by B = I{(Y (0), Y (1)) ∈ B}, where I{·} is the indicator
function and B is the set of desirable outcomes. Note that B is by defi-
nition a comparison of the two potential outcomes. For a binary outcome,
B might be an indicator for Y (0) < Y (1) or Y (0) ≤ Y (1), depending on
which treatment is preferable with identical (efficacy) outcomes. In our ex-
ample, we set B = I{Y (0)≤ Y (1)} because rilpivirine is thought to have a
better safety profile and will likely be preferred over efavirenz when their
efficacy outcomes are identical. For a continuous outcome, we might take
B = {(y0, y1) :y1−y0 > δ}, where δ reflects considerations of cost, clinical sig-
nificance and possibly the safety profiles of the two treatments (if not incor-
porated into a vector-valued outcome). For an ordered categorical outcome,
the definition of B may be more complicated. We shall take the definition of
B as given and focus on the evaluation of Z for predicting B. The target B
is an intrinsic characteristic of an individual patient, which suggests that Z
can be evaluated using well-known quantities in prediction and classification
[e.g., Zhou, Obuchowski and McClish (2002), Pepe (2003), Zou et al. (2011)].
For a binary marker, it makes sense to consider the true and false positive
rates, defined as TPR=P(Z = 1|B = 1) and FPR= P(Z = 1|B = 0), respec-
tively. For a continuous marker, it is customary to consider the ROC curve
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defined as
ROC(s) = 1−FZ|B=1{F
−1
Z|B=0(1− s)}.
Here and in the sequel, we use F to denote a generic (conditional) distri-
bution function, with the subscript indicating the random variable(s) con-
cerned. The ROC curve is simply a plot of TPR versus FPR for classifiers
of the form I(Z > z), with the threshold z ranging over all possible values.
Because B is never observed, the existing methodology for evaluating pre-
dictors, which generally assumes that B can be observed, cannot be used
directly to evaluate a predictive biomarker. Nonetheless, we note that TPR,
FPR and ROC are all determined by FZ|B , which can be recovered using
Bayes’ rule from the marginal distribution of Z and the conditional prob-
ability piZ(z) = P(B = 1|Z = z). For a binary marker, 1− piZ(0) and piZ(1)
are negative and positive predictive values, respectively,
TPR =
τpiZ(1)
τpiZ(1) + (1− τ)piZ(0)
,
(1)
FPR =
τ{1− piZ(1)}
τ{1− piZ(1)}+ (1− τ){1− piZ(0)}
,
where τ =P(Z = 1). For a continuous marker, we have
FZ|B=1(z0) =
∫ z0
−∞
piZ(z)dFZ(z)
/∫ ∞
−∞
piZ(z)dFZ(z),
(2)
FZ|B=0(z0) =
∫ z0
−∞
{1− piZ(z)}dFZ(z)
/∫ ∞
−∞
{1− piZ(z)}dFZ(z).
Since Z is fully observed, the identifiability of FZ|B would follow from that of
piZ(z). Once an estimate of piZ(z) is available, it can be substituted into the
above displays together with an empirical estimate of τ or FZ , depending
on the nature of Z.
Despite its simple appearance, piZ(z) is not straightforward to estimate.
In fact, for any conceivable form of B, the quantity piZ(z) = P{(Y (0), Y (1)) ∈
B|Z = z} is not empirically identifiable because it involves the joint distribu-
tion of Y (0) and Y (1) given Z = z. Owing to randomization, it is straight-
forward to identify
Ft|Z(y|z) = P{Y (t)≤ y|Z = z}=P(Y ≤ y|T = t,Z = z)
for each t ∈ {0,1}, and to estimate it from a regression analysis for Y given
T and Z. However, the dependence structure of Y (0) and Y (1) given Z = z
is not identifiable from the data [e.g., Gadbury and Iyer (2000)], which is
also known as the fundamental problem of causal inference [Holland (1986)].
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Because piZ(z) is not determined by the “marginals” Ft|Z (t= 0,1), its identi-
fication and estimation require additional information or assumptions about
the dependence between Y (0) and Y (1) given Z = z. For a binary outcome,
this can be achieved by assuming monotonicity [i.e., Y (0)≤ Y (1) with prob-
ability 1] as in Huang, Gilbert and Janes (2012). The monotonicity assump-
tion corresponds to maximal positive dependence of Y (0) and Y (1).
For a general outcome and without assuming monotonicity, we develop
alternative methods by adapting the techniques of Dodd and Pepe (2003)
and Zhang et al. (2013). To account for the dependence of Y (0) and Y (1),
we start by conditioning on relevant covariates that are associated with both
outcomes. Let X denote a vector of such covariates measured at baseline,
which may include prognostic factors and effect modifiers. In the THRIVE
study, X may include gender, race, and baseline age and body mass index.
We include Z as a component of X and write X= (Z,W), where W con-
sists of the additional baseline covariates. Writing piX(x) = P{(Y (0), Y (1)) ∈
B|X= x}, a conditioning argument yields
piZ(z) = E{piX(X)|Z = z}=
∫
piX(z,w)FW |Z(dw|z).(3)
Because FW |Z is empirically identifiable and estimable, the challenge now is
to identify and estimate piX(x).
If X is sufficient for explaining the dependence between Y (0) and Y (1),
then we can expect that
Y (0)⊥ Y (1)|X,(4)
that is, that Y (0) and Y (1) are conditionally independent given X. This
assumption cannot be verified with the observed data and must be based on
external information. Under assumption (4), the joint distribution of Y (0)
and Y (1) given X is determined by the “marginals”
Ft|X(y|x) = P{Y (t)≤ y|X= x}=P(Y ≤ y|T = t,X= x) (t= 0,1),
which are straightforward to identify and estimate. In reality, assumption (4)
can be violated becauseX may not explain all the dependence between Y (0)
and Y (1). Such violations can be examined in a sensitivity analysis based
on a latent variable that accounts for any residual dependence between Y (0)
and Y (1). Under this approach, assumption (4) is relaxed as follows:
Y (0)⊥ Y (1)|(X,U),(5)
where U is a subject-specific latent variable that is independent of X. In
other words, U represents what is missing from X that makes assumption
(4) break down. Assumption (5) alone is not sufficient to identify piX(x)
because U is unobserved. However, by specifying certain quantities related
to U , we can perform a sensitivity analysis based on assumption (5), as we
demonstrate in the next section.
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3. Methodology. We now describe methods for estimating the aforemen-
tioned performance measures (TPR, FPR and ROC). As indicated earlier,
we will start by estimating piX(x) under assumptions (4) and (5). This can
be done using a direct approach and an indirect approach, to be described
in Sections 3.1 and 3.2, respectively. The direct and indirect approaches are
based on models for piX(x) and FY |T,X(y|t,x), respectively, which we refer
to as benefit and outcome models. A benefit model is directly informative
about piX(x) and thus more interpretable in the present context, while an
outcome model is more familiar to practitioners and easier to estimate and
validate using standard techniques. Further comments comparing the two
approaches are given at the end of Section 3.2 after the approaches are
described and in Section 5. In Section 3.3 we show how to convert an esti-
mate of piX(x) into one of piZ(z). Estimates of the performance measures of
interest are given in Section 3.4.
3.1. Direct estimation of piX(x) based on a Benefit model. A benefit
model is a parametric model for P(B = 1|X) = P{(Y (0), Y (1)) ∈ B|X}, such
as the following generalized linear model (GLM):
piX(X;α) = ψ(α1 +α
′
XX),(6)
where α = (α1,α
′
X)
′ is the regression parameter and ψ is an inverse link
function. Since B is binary, the probit and logit links are natural choices.
Suppose the conditional independence assumption (4) holds. To gain some
intuition, consider a discrete X taking values in {x1, . . . ,xK}. Within each
stratum defined by X= xk, assumption (4) implies that Y (0) and Y (1) are
independent of each other, as if they arise from different subjects, which we
assume are independent. In other words, given that Xi =Xj , the natural
pair (Yi(0), Yi(1)) is identically distributed as the artificial pair (Yi(0), Yj(1)).
If Ti = 0 and Tj = 1, then (Yi(0), Yj(1)) is observable as (Yi, Yj), so that
piX(xk) = E(B|X= xk) can be estimated by
1
n0kn1k
∑
i∈S0k
∑
j∈S1k
Bij,(7)
where Bij = I{(Yi, Yj) ∈ B}, Stk = {i :Ti = t,Xi = xk}, and ntk denotes the
size of Stk (t= 0,1; k = 1, . . . ,K).
The question is how to generalize this idea to a nondiscrete X. To follow
the logic of (7), one would need to find subjects from different treatment
groups with the same value ofX, which becomes difficult whenX has contin-
uous components (4 in our example). To overcome that problem, we borrow
ideas from Dodd and Pepe (2003), who consider semiparametric regression
for the area under the ROC curve, and work with an expanded model given
by
P(Bij = 1|Xi,Xj ;β) = ψ{β1 + β
′
X(Xi +Xj)/2 + β
′
dX(Xj −Xi)},(8)
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where β = (β1,β
′
X ,β
′
dX)
′, i ∈ S0k and j ∈ S1k. The new features of model
(8) relative to model (6) are introduced for the sole purpose of estimating
α. Our research question does not pertain to the left-hand side of (8) or the
regression coefficient βdX . However, assumption (4) implies that P(Bij =
1|Xi =Xj = x) = P(B = 1|X= x). Thus, when Xi =Xj , model (8) reduces
to model (6) with
α= (β1,β
′
X)
′.(9)
In that sense, model (8) is a helper model that allows us to estimate model
(6) with the observed data. Let St = {i :Ti = t} and let nt denote the size of
St (t= 0,1). Then the regression parameter β in model (8) can be estimated
by solving the equation
0 =
∑
i∈S0
∑
j∈S1
∂piij
∂β
Bij − piij
piij(1− piij)
,(10)
where
piij = ψ{β1 + β
′
X(Xi +Xj)/2 + β
′
dX(Xj −Xi)}.
As suggested by Dodd and Pepe (2003), equation (10) need not include
all possible pairs (i, j); it could be based on a subset of pairs such that
‖Xi −Xj‖ < ε, where ‖ · ‖ denotes Euclidean norm, for some ε > 0. The
choice of ε represents a bias-variance trade-off, where a larger ε leads to
better efficiency and stability and also more sensitivity to the last component
of model (8).
The approach just described relies heavily on the conditional indepen-
dence assumption (4), which relates model (8) to model (6) through equation
(9). Equation (9) does not hold when assumption (4) is violated. However,
under alternative assumptions, we have
α= γ(β1,β
′
X)
′(11)
for a scalar γ. The key assumptions for (11) include assumption (5) and a
GLM-like structure analogous to model (6):
P(B = 1|X,U ;α∗) = ψ(α∗1 +β
∗′
XX+α
∗
UU),(12)
where α∗ = (α∗1,α
∗′
X , α
∗
U )
′. In Section A of the supplemental article [Zhang
et al. (2014)], we state additional assumptions that lead to (11) and give an
expression for γ. Since β is identifiable and estimable using the techniques
described earlier, α can be estimated as soon as γ is known or estimated.
Unfortunately, γ is unidentifiable from the observed data. For the probit and
logit links, we show in Section A of the supplemental article [Zhang et al.
(2014)] that γ can take any value greater than 2−1/2 ≈ 0.71. Thus, when
assumption (4) is in doubt, we can perform a sensitivity analysis based on
specified values of γ ∈ (2−1/2,∞), with γ = 1 corresponding to conditional
independence.
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3.2. Indirect estimation of piX(x) based on an outcome model. An out-
come model is a parametric model, say, FY |T,X(y|t,x;θ), for the conditional
distribution of Y given T and X, specified up to a finite-dimensional pa-
rameter θ. Let fY |T,X(y|t,x;θ) denote the associated probability density or
mass function. A typical outcome model would be a GLM with the following
mean structure:
E(Y |T,X;θ) = ψ{θ1+ θTT + θ
′
XX+ θ
′
TX(TX)},(13)
where θ = (θ1, θT ,θ
′
X ,θ
′
TX)
′ and ψ is an inverse link function. The parameter
θ can be estimated by maximizing the likelihood
∏n
i=1 fY |T,X(Yi|Ti,Xi;θ),
and the resulting maximum likelihood estimate (MLE) will be denoted by
θ̂. Because of randomization, the outcome model FY |T,X(y|t,x;θ) implies
that
Ft|X(y|x) = P{Y (t)≤ y|X= x}= FY |T,X(y|t,x;θ) (t= 0,1),
which can be estimated by substituting θ̂ for θ.
Under the conditional independence assumption (4), the joint distribution
F·|X(y0, y1|x) = P{Y (0)≤ y0, Y (1)≤ y1|X= x}
is identified as
F0|X(y0|x)F1|X(y1|x) = FY |T,X(y0|0,x;θ)FY |T,X(y1|1,x;θ)
and estimated by replacing θ with θ̂. Write
F̂CI·|X(y0, y1|x) = FY |T,X(y0|0,x; θ̂)FY |T,X(y1|1,x; θ̂),
where the superscript CI stands for conditional independence. The corre-
sponding estimate of piX(x) is then given by∫
I{(y0, y1) ∈ B}F̂
CI
·|X(dy0, dy1|x) =: F̂
CI
·|X(B|x).
When assumption (4) is in doubt, we can perform a sensitivity analysis
based on assumption (5), which implies that
F·|X(y0, y1|x) =
∫
F·|X,U (y0, y1|x, u)FU (du)
(14)
=
∫
F0|X,U (y0|x, u)F1|X,U (y1|x, u)FU (du),
where we generalize the previous notation in an obvious way (with U as an
additional conditioning variable). This suggests that we specify a model, say,
FY |T,X,U(y|t,x, u;θ
∗), for the conditional distribution of Y given (T,X,U),
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with a finite-dimensional parameter θ∗. Analogous to the GLM (13), we
work with a generalized linear mixed model (GLMM) with
E(Y |T,X,U ;θ∗) = ψ{θ∗1 + θ
∗
TT + θ
∗′
XX+ θ
∗′
TX(TX) + θ
∗
UU},(15)
where θ∗ = (θ∗1, θ
∗
T ,θ
∗′
X ,θ
∗′
TX , θ
∗
U)
′. The GLMM is not completely identified
without additional information, and we propose a sensitivity analysis based
on specified values of θ∗U (or, rather, |θ
∗
U |), which is described in Section B
of the supplemental article [Zhang et al. (2014)].
It is worth mentioning that the random effect U has a different interpre-
tation here than in Section 3.1. In model (15), U represents an unobserved
prognostic factor which affects both potential outcomes in the same direc-
tion; a change in U may or may not have much effect on the treatment
benefit B, depending on the precise definition of B and model (15). Al-
though one could incorporate a random treatment effect into model (15),
the resulting method will likely become very complicated. In model (12), U
acts like an effect modifier in that a change in U leads directly to a change
in the probability of a desirable treatment benefit. (Here we use the term
effect modifier in a heuristic sense which may or may not agree with an
interaction-based definition.) Thus, aside from modeling assumptions, the
direct and indirect approaches also differ in how they deal with departures
from assumption (4). The indirect approach is designed to address viola-
tions of assumption (4) due to an unmeasured prognostic factor, whereas
the direct approach is more appropriate for violations of assumption (4) due
to an unmeasured effect modifier.
3.3. Estimation of piZ(z). Equations (1) and (2) suggest that evaluation
of a predictive biomarker Z can be based on piZ(z) = P(B = 1|Z = z) and the
marginal distribution of Z. Because the latter is straightforward to estimate,
this section is focused on estimation of piZ(z) with a given estimate of piX(x),
say, piX(x), which may be obtained using any one of the proposed methods.
For a binary marker, equation (3) suggests that piZ(z) can be estimated by∑n
i=1 I{Zi = z}piX(z,Wi)/
∑n
i=1 I{Zi = z}. We therefore assume that Z is
continuous in the rest of this section.
We propose to estimate piZ(z) by substituting an estimate of FW |Z into
equation (3). One could specify a parametric model for FW |Z , however, this
can be difficult because the dimension of W can be rather large (5 in our
example). We therefore exploit the fact that Z is only one-dimensional and
employ nonparametric regression techniques in estimating FW |Z . Let ξ :R→
[0,∞) be a kernel function and λ > 0 a bandwidth parameter. Then we can
estimate FW |Z(w|z) by∑n
i=1 ξ{(Zi − z)/λ}I(Wi ≤w)∑n
i=1 ξ{(Zi − z)/λ}
.
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This, together with piX(x), can be substituted into equation (3) to estimate
piZ(z) as
piZ(z) =
∑n
i=1 ξ{(Zi − z)/λ}piX (z,Wi)∑n
i=1 ξ{(Zi − z)/λ}
.
An important question here is how to choose the bandwidth λ, for which
we propose a cross-validation approach. The estimate piZ(z) can be regarded
as a nonparametric regression of piX(Z,W) on Z, and its predictive accuracy
can be assessed by comparing the “response” B˜i = piX(Xi) with the estimate
B̂i = piZ(Zi). We propose to partition the sample into a training set and a
validation set and choose a value of λ that minimizes the average of (B˜i −
B̂i)
2 in the validation set with piZ(z) estimated from the training set using
bandwith λ.
3.4. Estimation of TPR, FPR and ROC. Given piZ(z) from Section 3.3,
the parameters of interest can be estimated using equations (1) and (2). For
a binary marker, this leads to
T̂PR =
τ̂piZ(1)
τ̂piZ(1) + (1− τ̂)piZ(0)
,
F̂PR =
τ̂{1− piZ(1)}
τ̂{1− piZ(1)}+ (1− τ̂){1− piZ(0)}
,
where τ̂ = n−1
∑n
i=1Zi. For a continuous marker, we have
R̂OC(s) = 1− F̂Z|B=1{F̂
−1
Z|B=0(1− s)},
where
F̂Z|B=1(z0) =
n∑
i=1
I(Zi ≤ z0)piZ(Zi)
/ n∑
i=1
piZ(Zi),
F̂Z|B=0(z0) =
n∑
i=1
I(Zi ≤ z0){1− piZ(Zi)}
/ n∑
i=1
{1− piZ(Zi)}.
An asymptotic analysis of these estimates can be rather tedious, espe-
cially because piZ(z) involves smoothing and cross-validation. For inference,
we recommend the use of bootstrap confidence intervals. To account for
all variability in the estimates, the entire estimation procedure, including
bandwidth selection based on cross-validation, should be repeated for each
bootstrap sample.
4. Application to the THRIVE study. We now apply the methods of
Section 3 to the THRIVE study introduced in Section 1, a randomized,
double-blind, double-dummy, noninferiority trial at 98 hospitals or medical
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centers in 21 countries [Cohen et al. (2011)]. The THRIVE study compared
rilpivirine with efavirenz for treating HIV-1 in treatment-naive adults, in the
presence of common background nucleoside or nucleotide reverse transcrip-
tase inhibitors (N[t]RTIs). The study enrolled 680 adult patients who were
naive to antiretroviral therapy, with a screening viral load of at least 5000
copies per ml and viral sensitivity to N(t)RTIs. The patients were random-
ized in a 1 : 1 ratio to receive oral rilpivirine 25 mg once daily or efavirenz 600
mg once daily, in addition to an investigator-selected regimen of background
N(t)RTIs.
The outcome of interest to us is virologic response (viral load below 50
copies/ml) at week 48 of treatment, with patient discontinuation (about
5%) counted as failure. The observed virologic response rates are 86% and
82% in the rilpivirine and efavirenz groups, respectively, and the difference
between the two groups (3.5%; 95% CI: −1.7–8.8%) meets a prespecified
noninferiority criterion based on a 12% margin (p < 0.0001). Thus, rilpivirine
appears comparable to, if not better than, efavirenz in terms of population-
level efficacy. However, Figure 1 suggests that individual patients respond
differently to the two therapies and that baseline viral load and CD4 cell
count could be used as predictive biomarkers. As indicated earlier, we will
for safety reasons define individual-level treatment benefit as B = I{Y (0)≤
Y (1)}, where Y (0) and Y (1) denote potential outcomes for efavirenz and
rilpivirine, respectively.
Baseline viral load and CD4 cell count are both log-transformed before
entering the benefit and outcome models as covariates. In addition to these
biomarkers, the covariate vector X also includes gender, race (black, white
or other), age and body mass index at baseline. For the direct approach of
Section 3.1, the benefit model is a logistic regression model given by (6),
with the aforementioned covariates as linear terms (and no interactions),
and the helper model is given by (8) with the same link. For the indirect
approach of Section 3.2, the outcome model is a logistic regression model
similar to (13) except that interactions of X with T are limited to the two
biomarkers. The selection of covariates and interactions in these models is
based on subject matter knowledge and not on statistical tests. Estimation
of model (8) is based on the 1% of pairs (of control and experimental pa-
tients) that are most similar in terms of ‖Xi −Xj‖, as suggested by Dodd
and Pepe (2003). (Other proportions, from 0.001 to 1, have been attempted
without yielding a material difference.) Under the indirect approach, the
simplified method in Web Appendix B is used to estimate θ∗ for a given
θ∗U . In any case, estimates of piX(x) are converted into estimates of piZ(z)
using the kernel smoothing method of Section 3.3, with a Gaussian kernel
and a cross-validated bandwidth. The cross-validation is based on a 1 : 1
random partition of the sample into a training set and a validation set, and
the bandwidth is chosen among {2l sd(Z) : l=−5, . . . ,5} using the minimum
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mean squared error criterion. The formulas of Section 3.4 are used to ob-
tain estimates of ROC curves, and the trapezoidal rule is then employed
in calculating the associated AUCs. The above procedure is performed for
both biomarkers on the original sample as well as 200 bootstrap samples.
Pointwise 90% confidence intervals for ROC curves are obtained using a
simple bootstrap percentile method, and bootstrap standard errors are used
for inference on AUCs (and AUC differences between the two biomarkers).
Figure 2 gives a side-by-side comparison of ROC curves for the two
biomarkers, estimated using the direct approach of Section 3.1 with γ =
0.71,1,2,4. The value γ = 1 corresponds to assumption (4) of conditional
independence, while the value 0.71 is a theoretical lower bound. The asso-
ciated AUC estimates and standard errors are shown in the upper half of
Table 1. Both Figure 2 and the relevant portion of Table 1 show that the two
biomarkers are useful as predictive biomarkers, with ROC curves above the
diagonal and AUCs greater than 0.5 after accounting for sampling variabil-
ity. The performance of each biomarker does appear to depend heavily on the
value of γ; the AUC estimate increases dramatically with increasing γ. This
pattern is confirmed by additional analyses based on other values of γ (re-
sults not shown). Given the remarks at the end of Section 3.2, these results
suggest that evaluation of a predictive biomarker can be rather sensitive to
an unmeasured effect modifier. On the other hand, for each value of γ, the
AUC estimate for baseline viral load is higher than that for baseline CD4 cell
count, although the difference is not statistically significant. These results
suggest that comparison of predictive biomarkers may be less sensitive to
the choice of γ, even though this particular data set does not provide strong
evidence that baseline viral load is better than baseline CD4 cell count as
a predictive biomarker. Whether we are evaluating a single marker or com-
paring two markers, there is an obvious relationship between increasing γ
and greater variability in the estimates, as indicated by widening confidence
intervals in Figure 2 and increasing standard errors in Table 1.
Figure 3 gives another comparison of the two biomarkers based on ROC
curves estimated using the indirect approach of Section 3.2 with θ∗U = 0,1.8,
4,8. Here, the value θ∗U = 0 corresponds to conditional independence, and
the value 1.8 is a lower confidence bound (to be discussed later). The as-
sociated AUC estimates and standard errors are shown in the lower half of
Table 1. These results are consistent with those from the direct approach
in suggesting that both biomarkers are useful as predictive biomarkers. In
particular, the results for conditional independence (θ∗U = 0) are fairly con-
sistent with their counterparts under the direct approach (with γ = 1). Like
Figure 2, Figure 3 also shows an increasing trend for the predictive perfor-
mance of each biomarker as a function of the sensitivity parameter θ∗U . The
trend is confirmed for additional values of θ∗U , although the results are not
shown. Thus, considering the remarks at the end of Section 3.2, it appears
EVALUATING PREDICTIVE BIOMARKERS 15
Fig. 2. ROC analysis of the THRIVE data using the direct approach: estimated ROC
curves (solid lines) and 90% pointwise confidence intervals (dashed lines) for baseline viral
load (RNA, left) and CD4 cell count (right), with different values of γ.
that evaluation of a predictive biomarker can also be sensitive to an unmea-
sured prognostic factor. The results from the indirect approach reinforce the
previous observation that baseline viral load appears to perform better than
baseline CD4 cell count, although the differences here also fail to reach sta-
tistical significance. As is the case with the direct approach, increasing θ∗U
tends to produce greater variability in the estimates.
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Table 1
AUC analysis of the THRIVE data: point estimates and bootstrap standard errors for the
AUCs of baseline viral load (RNA) and CD4 cell count as well as their difference
(RNA–CD4), obtained using the direct approach of Section 3.1 and the indirect approach
of Section 3.2 with sensitivity parameters γ and θ∗U , respectively
Sensitivity
parameter
Point estimate Standard error
RNA CD4 Diff. RNA CD4 Diff.
γ Direct approach
0.71 0.61 0.58 0.03 0.04 0.03 0.03
1 0.65 0.63 0.03 0.05 0.04 0.05
2 0.77 0.75 0.02 0.06 0.08 0.08
4 0.88 0.80 0.08 0.07 0.10 0.13
θ∗U Indirect approach
0 0.64 0.59 0.05 0.04 0.04 0.05
1.8 0.65 0.60 0.06 0.05 0.05 0.05
4 0.68 0.64 0.04 0.07 0.07 0.08
8 0.72 0.70 0.02 0.09 0.09 0.11
Although the uncertainty in comparing the two biomarkers could poten-
tially be reduced by an increased sample size, some uncertainty will likely
remain in evaluating each individual marker, given the apparent dependence
on sensitivity parameters. Nonetheless, the increasing trend observed under
both approaches suggests that a lower bound for predictive performance may
be available under each approach. For the direct approach, the lower bound
is given by γ = 0.71, as noted in Section 3.1. For the indirect approach, a
lower bound for θ∗U (and hence for the performance of each biomarker) may
be available from longitudinal data (see Web Appendix B). For the THRIVE
study, the lower bound for θ∗U is estimated as 2.5 (95% CI: 1.8–3.7, based
on 1000 bootstrap samples) from a GLMM analysis of repeated measure-
ments at 24, 32, 40 and 48 weeks. Although earlier measurements (baseline
through 20 weeks) are also available, we restrict our analysis to the later mea-
surements in order to reduce misspecification bias; see Zhang et al. [(2013),
Section 4] for a detailed explanation of this strategy. This GLMM analysis
suggests that, under the additional assumptions given in Web Appendix B,
the value θ∗U = 1.8 represents the worst case scenario for the indirect ap-
proach. The corresponding ROC and AUC estimates are better than those
for γ = 0.71 under the direct approach and thus more informative as lower
bounds.
Our ROC analyses under both (direct and indirect) approaches also illus-
trate that measures of predictive accuracy need not correlate with interac-
tions. Although baseline CD4 cell count exhibits a more dramatic interaction
in Figure 1, there is no indication (in the same data set) that it outperforms
baseline viral load as a predictive biomarker.
EVALUATING PREDICTIVE BIOMARKERS 17
Fig. 3. ROC analysis of the THRIVE data using the indirect approach: estimated ROC
curves (solid lines) and 90% pointwise confidence intervals (dashed lines) for baseline viral
load (RNA, left) and CD4 cell count (right), with different values of θ∗U .
5. Discussion. In this article we have proposed new methods for evalu-
ating predictive biomarkers in the potential outcome framework of Huang,
Gilbert and Janes (2012). Instead of monotonicity, our starting point is
conditional independence of potential outcomes given observed covariates.
Possible departures from the latter assumption can be addressed by incor-
porating a random effect that accounts for any residual dependence between
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potential outcomes. Because the random effect models are not completely
identifiable, we propose a sensitivity analysis approach based on quantities
related to the random effect. Our analysis of the THRIVE data reveals a
great deal of sensitivity for the performance of each individual biomarker and
much less sensitivity for the comparison of the two markers. Despite the un-
certainty about individual biomarkers, the lower bounds on their predictive
performance, available under both (direct and indirect) approaches, show
that they are both useful as predictive biomarkers. For comparing the two
markers, our analysis does not show much sensitivity and does not indicate
a significant difference in the predictive performance of the two markers.
There does appear to be a lot of sensitivity (particularly in the upper
portion) in quantifying the performance of an individual marker. Such sen-
sitivity introduces additional uncertainty into the overall conclusion of the
analysis, which is certainly undesirable. We see this as a reminder of the
inherent limitation of the observed data for answering certain questions. As
in many other statistical problems (e.g., missing data, censoring, confound-
ing), the parameters of interest to us are not identifiable from the observed
data without making untestable assumptions. When such assumptions are
in doubt, the parameters are partially identified and the associated inference
cannot be as sharp as that for point-identified parameters [Manski (2003)]. It
may be disappointing to see that different assumptions (about the sensitiv-
ity parameter) can lead to a wide range for the parameter of interest. On the
other hand, one could argue that the sensitivity analysis serves its purpose
well by revealing the limitation of the available data and information.
In theory, point identification is achieved under the conditional inde-
pendence assumption (6), which requires that the observed covariates be
sufficient for explaining the dependence between the potential outcomes.
Although we may never be certain that assumption (6) holds, it seems rea-
sonable to believe that the assumption will get close to being true with a
growing set of relevant covariates obtained from increasing knowledge of
the disease. The more we know about the disease, the more information we
have about relevant covariates, the more confidence we should be able to
place in assumption (6). In practice, it may be difficult to determine when
we have sufficient information to rely on assumption (6) and when we have
to perform a sensitivity analysis. One possible solution would be a Bayesian
approach with an informative prior on the sensitivity parameter which quan-
tifies our uncertainty about assumption (6). As we become more confident
about assumption (6), the prior will become more concentrated at or near
that assumption.
Each of the direct and indirect approaches has unique advantages. The
direct approach is able to accommodate complex definitions of treatment
benefit involving several outcome variables of arbitrary types, as long as
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they are all observed. The indirect approach is best suited for a single out-
come of primary interest. Although the outcome model can include multiple
outcomes in principle, their dependence structure can be difficult to specify
and estimate. Even for a single outcome, the indirect approach requires a
greater amount of modeling (in the sense that an outcome model implies
a benefit model) and is therefore more prone to misspecification bias. On
the other hand, the indirect approach is able to use all the information in
the observed outcome data and therefore may have an efficiency advantage.
Finally, for sensitivity analysis, the direct approach is more appropriate for
an unmeasured effect modifier, and the indirect approach for an unmeasured
prognostic factor. In practice, we recommend that both approaches be used
in a complementary fashion, as in our analysis of the THRIVE data.
A reviewer has pointed out that some elements of personal judgment may
be involved in choosing among different treatments. While this is not a ma-
jor issue in the THRIVE data, where the definition of a treatment benefit is
quite objective, it can certainly become a major issue in other therapeutic
areas such as weight loss. For example, some patients may be willing to ac-
cept the extra risks of a surgical procedure (relative to a nonsurgical one) for
an additional loss of 20 pounds, while others may not. To incorporate such
personal judgment into the proposed approach, we could allow δ to vary
across patients, and we would need to be able to measure δ for individual
patients or at least be able to predict δ using measurable individual char-
acteristics. In the latter case, the methodology will need to be modified to
incorporate a prediction model for δ and the associated variability. It will be
of interest to explore that possibility in the context of a suitable application.
Because of the complexity of the proposed methodology, a sample size
formula is not yet available; however, for a given application, one could
perform a simulation study to gauge the adequacy (in terms of power and
precision) of a proposed sample size. Such an assessment should obviously
consider the objective of the analysis (e.g., evaluating a single biomarker
versus comparing two or more biomarkers). In addition, the nonparametric
regression in Section 3.3 may imply a higher requirement on the sample size
than do the other parts of the methodology, which are based on parametric
regression techniques. A sample size that is inadequate for one-dimensional
nonparametric regression may compromise the performance of the methods.
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SUPPLEMENTARY MATERIAL
Supplement: Technical details (DOI: 10.1214/14-AOAS773SUPP; .pdf).
We provide technical details concerning the sensitivity analyses in Sec-
tions 3.1 and 3.2.
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